WO2001094629A3 - Cancer gene determination and therapeutic screening using signature gene sets - Google Patents

Cancer gene determination and therapeutic screening using signature gene sets Download PDF

Info

Publication number
WO2001094629A3
WO2001094629A3 PCT/US2001/010838 US0110838W WO0194629A3 WO 2001094629 A3 WO2001094629 A3 WO 2001094629A3 US 0110838 W US0110838 W US 0110838W WO 0194629 A3 WO0194629 A3 WO 0194629A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
sets
gene
expression
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/010838
Other languages
French (fr)
Other versions
WO2001094629A8 (en
WO2001094629A2 (en
Inventor
Paul E Young
Meena Augustus
Kenneth C Carter
Reinhard Ebner
Greg Endress
Steve Horrigan
Daniel R Soppet
Zoe Weaver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Data Inc
Original Assignee
Avalon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals Inc filed Critical Avalon Pharmaceuticals Inc
Priority to JP2002502169A priority Critical patent/JP2004509612A/en
Priority to EP01938990A priority patent/EP1358349A2/en
Priority to AU2001264559A priority patent/AU2001264559A1/en
Priority to CA002411601A priority patent/CA2411601A1/en
Publication of WO2001094629A2 publication Critical patent/WO2001094629A2/en
Publication of WO2001094629A8 publication Critical patent/WO2001094629A8/en
Anticipated expiration legal-status Critical
Publication of WO2001094629A3 publication Critical patent/WO2001094629A3/en
Priority to US10/843,641 priority patent/US20050064454A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Processes for assaying potential antitumor agents based on their modulation of the expression of specified genes, or sets, of suspected cancer cell genes are disclosed, along with methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, or sets of genes. Also disclosed are methods for determining functionally related genes, or gene sets, as well as methods for treating cancer based on targeting expression products of such genes, or gene sets, and determining genes involved in the cancerous process.
PCT/US2001/010838 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets Ceased WO2001094629A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002502169A JP2004509612A (en) 2000-06-05 2001-05-30 Oncogene determination and therapeutic screening using characteristic genes
EP01938990A EP1358349A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
AU2001264559A AU2001264559A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
CA002411601A CA2411601A1 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets
US10/843,641 US20050064454A1 (en) 2000-06-05 2004-05-11 Cancer gene determination and therapeutic screening using signature gene sets

Applications Claiming Priority (84)

Application Number Priority Date Filing Date Title
US20947300P 2000-06-05 2000-06-05
US20953100P 2000-06-05 2000-06-05
US60/209,473 2000-06-05
US60/209,531 2000-06-05
US23361700P 2000-09-18 2000-09-18
US23313300P 2000-09-18 2000-09-18
US60/233,133 2000-09-18
US60/233,617 2000-09-18
US23405200P 2000-09-20 2000-09-20
US23403400P 2000-09-20 2000-09-20
US23400900P 2000-09-20 2000-09-20
US60/234,009 2000-09-20
US60/234,052 2000-09-20
US60/234,034 2000-09-20
US23450900P 2000-09-22 2000-09-22
US23456700P 2000-09-22 2000-09-22
US60/234,509 2000-09-22
US60/234,567 2000-09-22
US23492400P 2000-09-25 2000-09-25
US23513400P 2000-09-25 2000-09-25
US23508200P 2000-09-25 2000-09-25
US23492300P 2000-09-25 2000-09-25
US23507700P 2000-09-25 2000-09-25
US23528000P 2000-09-25 2000-09-25
US60/235,082 2000-09-25
US60/235,134 2000-09-25
US60/235,280 2000-09-25
US60/234,924 2000-09-25
US60/234,923 2000-09-25
US60/235,077 2000-09-25
US23563700P 2000-09-26 2000-09-26
US23563800P 2000-09-26 2000-09-26
US60/235,637 2000-09-26
US60/235,638 2000-09-26
US23586300P 2000-09-27 2000-09-27
US23584000P 2000-09-27 2000-09-27
US23572000P 2000-09-27 2000-09-27
US23571100P 2000-09-27 2000-09-27
US60/235,840 2000-09-27
US60/235,863 2000-09-27
US60/235,720 2000-09-27
US60/235,711 2000-09-27
US23603200P 2000-09-28 2000-09-28
US23603300P 2000-09-28 2000-09-28
US23603400P 2000-09-28 2000-09-28
US23611100P 2000-09-28 2000-09-28
US23602800P 2000-09-28 2000-09-28
US23610900P 2000-09-28 2000-09-28
US60/236,111 2000-09-28
US60/236,109 2000-09-28
US60/236,034 2000-09-28
US60/236,033 2000-09-28
US60/236,032 2000-09-28
US60/236,028 2000-09-28
US23684200P 2000-09-29 2000-09-29
US23689100P 2000-09-29 2000-09-29
US60/236,891 2000-09-29
US60/236,842 2000-09-29
US23727800P 2000-10-02 2000-10-02
US23717200P 2000-10-02 2000-10-02
US23729400P 2000-10-02 2000-10-02
US23717300P 2000-10-02 2000-10-02
US23731600P 2000-10-02 2000-10-02
US23729500P 2000-10-02 2000-10-02
US60/237,278 2000-10-02
US60/237,295 2000-10-02
US60/237,173 2000-10-02
US60/237,172 2000-10-02
US60/237,316 2000-10-02
US60/237,294 2000-10-02
US23760600P 2000-10-03 2000-10-03
US23760400P 2000-10-03 2000-10-03
US23759800P 2000-10-03 2000-10-03
US23760800P 2000-10-03 2000-10-03
US23742500P 2000-10-03 2000-10-03
US60/237,604 2000-10-03
US60/237,598 2000-10-03
US60/237,606 2000-10-03
US60/237,425 2000-10-03
US60/237,608 2000-10-03
US24508400P 2000-11-01 2000-11-01
US24486700P 2000-11-01 2000-11-01
US60/244,867 2000-11-01
US60/245,084 2000-11-01

Publications (3)

Publication Number Publication Date
WO2001094629A2 WO2001094629A2 (en) 2001-12-13
WO2001094629A8 WO2001094629A8 (en) 2002-05-16
WO2001094629A3 true WO2001094629A3 (en) 2003-09-04

Family

ID=27586968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010838 Ceased WO2001094629A2 (en) 2000-06-05 2001-05-30 Cancer gene determination and therapeutic screening using signature gene sets

Country Status (5)

Country Link
EP (1) EP1358349A2 (en)
JP (1) JP2004509612A (en)
AU (1) AU2001264559A1 (en)
CA (1) CA2411601A1 (en)
WO (1) WO2001094629A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601826B2 (en) 2002-09-30 2009-10-13 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1

Families Citing this family (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777537B1 (en) 1996-02-22 2004-08-17 Forsyth Dental Infirmary For Children Osteoclast proton pump subunit
US20040219569A1 (en) 1999-07-06 2004-11-04 Fruma Yehiely Gene identification method
US20020147143A1 (en) * 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030236209A1 (en) * 1998-03-18 2003-12-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
EP1623991A3 (en) * 1999-09-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP3964678B2 (en) 1999-10-28 2007-08-22 アジェンシス，インコーポレイテッド 36P6D5: Secretory tumor antigen
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US6953658B2 (en) 2000-03-09 2005-10-11 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancer
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US7235649B2 (en) * 2000-03-24 2007-06-26 Duke University Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same
CA2405431A1 (en) * 2000-03-31 2001-10-11 Gene Logic, Inc. Gene expression profiles in esophageal tissue
NZ521786A (en) * 2000-03-31 2004-07-30 Aventis Pharma Inc NFIF-14b and NFIF-7a (nuclear factor kappa B inducing factor) polypeptides and nulciec acids and their use in compositions for inhibiting inflammation
GB0018307D0 (en) 2000-07-26 2000-09-13 Aventis Pharm Prod Inc Polypeptides
EP1666492A1 (en) * 2000-06-02 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6524819B1 (en) * 2000-07-11 2003-02-25 Incyte Genomics, Inc. Down syndrome critical region 1-like proteins
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7291719B2 (en) 2000-07-25 2007-11-06 Genentech, Inc. PRO4332 antibodies
CA2416732C (en) 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
CA2417676A1 (en) * 2000-08-03 2002-02-14 Incyte Genomics, Inc. Sequences for integrin alpha-8
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
EP1402012A2 (en) * 2000-11-30 2004-03-31 Millennium Pharmaceuticals, Inc. Methods of using 18903 to treat pain and pain-related disorders
CA2431313A1 (en) * 2000-12-08 2002-08-01 Eos Biotechnology, Inc. Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20020137184A1 (en) * 2000-12-20 2002-09-26 Pe Corporation (Ny) Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and use thereof
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030194702A1 (en) * 2000-12-22 2003-10-16 Engelhard Eric K. Novel compositions and methods for cancer
US7645441B2 (en) 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7700274B2 (en) 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
CA2437750A1 (en) * 2001-02-08 2002-08-15 Tularik Inc. Prc17: an amplified cancer gene
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
EP1383543A4 (en) * 2001-03-23 2006-06-21 Agy Therapeutics Inc Use of biomolecular targets in the treatment and visualization of brain tumors
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20050059001A1 (en) * 2001-05-31 2005-03-17 Akira Nakagawara Nucleic acids isolated in neuroblastoma
CA2449275A1 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. Dgks as modifiers of the p53 pathway and methods of use
CA2633171C (en) 2001-06-20 2012-11-20 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
US20050272120A1 (en) * 2001-06-20 2005-12-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2537074T3 (en) 2001-09-06 2015-06-02 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
JP2005508160A (en) 2001-09-18 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Human tyrosine phosphatase family member MID4460 and uses thereof
WO2003035857A1 (en) * 2001-10-22 2003-05-01 Bayer Healthcare Ag Regulation of human nad-dependent alpha-glycerol-3-phosphate dehydrogenase
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ES2394018T3 (en) * 2001-11-27 2013-01-15 Ucb Pharma S.A. Procedures for the diagnosis and treatment of epithelial cell derived cancers
WO2003061573A2 (en) * 2002-01-18 2003-07-31 Millennium Pharmaceuticals, Inc. Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo
JP2005516073A (en) * 2002-02-01 2005-06-02 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド Modulation of type II β-phosphoinositide phosphate kinase
WO2003076579A2 (en) * 2002-03-06 2003-09-18 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
US20030215852A1 (en) * 2002-04-01 2003-11-20 Wyeth Novel pancortin-Pablo protein interactions and methods of use thereof
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US7329502B2 (en) 2002-04-25 2008-02-12 The United States Of America As Represented By The Department Of Health And Human Services ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
WO2003097878A1 (en) * 2002-05-21 2003-11-27 Sysmex Corporation Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers
EP1365247A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (AVPR3)
EP1365244A1 (en) * 2002-05-23 2003-11-26 Bayer Ag Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 2 (AVPR2)
AU2003238178A1 (en) 2002-05-29 2003-12-12 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Pancreas-specific proteins
AU2003245441A1 (en) * 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2003105783A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2004003564A2 (en) * 2002-06-26 2004-01-08 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
GB0216727D0 (en) 2002-07-17 2002-08-28 Univ Cambridge Tech Genes
AU2003252417A1 (en) * 2002-08-06 2004-03-03 Genox Research, Inc. Protease inhibitor
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2002951346A0 (en) * 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
ATE441713T1 (en) * 2002-09-27 2009-09-15 Dainippon Sumitomo Pharma Co TUMOR ANTIGEN PROTEIN AND USE THEREOF
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
AU2003278079A1 (en) * 2002-10-14 2004-05-04 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis
AU2003279312A1 (en) * 2002-10-24 2004-05-13 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
US7189524B1 (en) 2002-11-25 2007-03-13 Amgen, Inc. Receptor ligands and methods of modulating receptors
US20060104981A1 (en) * 2002-12-24 2006-05-18 Yuichi Hikichi Prophylactic/therapeutic agent for cancer
US7425624B1 (en) 2003-01-21 2008-09-16 Mayo Foundation For Medical Education And Research Sulfotransferase 1A3 sequence variants
EP1603514A4 (en) * 2003-01-24 2007-08-22 Bayer Pharmaceuticals Corp Expression profiles for colon cancer and methods of use
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DE10309729A1 (en) * 2003-02-26 2004-09-16 Hinzmann, Bernd, Dr. Human nucleic acid sequences from bladder cancer
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
AU2004219820B2 (en) * 2003-03-10 2008-06-12 Japan Science And Technology Agency Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker
US20040191782A1 (en) * 2003-03-31 2004-09-30 Yixin Wang Colorectal cancer prognostics
ITRM20030149A1 (en) 2003-04-02 2004-10-03 Giuliani Spa ANTISENSE OLIGONUCLEOTIDES (ODN) FOR SMAD7 AND THEIR USE IN THE MEDICAL FIELD
FR2853909A1 (en) * 2003-04-16 2004-10-22 Galderma Res & Dev Using polynucleotide probes based on the DPYSL3 gene (Dihydropyrimidinase-like 3), for diagnosis of psoriasis, or predisposition, and in screening for antipsoriatic agents
WO2004104224A2 (en) * 2003-05-21 2004-12-02 F. Hoffmann-La Roche Ag Markers for lxr activation
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
NZ588323A (en) * 2003-07-17 2012-04-27 Pacific Edge Biotechnology Ltd Markers for the detection of gastric cancer
WO2005013893A2 (en) * 2003-07-24 2005-02-17 Avalon Pharmaceuticals, Inc. Cancer related genes
EP1652923B1 (en) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
US20080050313A1 (en) * 2003-08-14 2008-02-28 Exelixis, Inc. Sulfs as Modifiers of the Beta-Catenin Pathway and Methods of Use
CA2475769C (en) * 2003-08-28 2018-12-11 Veridex, Llc Colorectal cancer prognostics
US20070178458A1 (en) * 2003-09-05 2007-08-02 O'brien Philippa Methods of diagnosis and prognosis of ovarian cancer II
WO2005054508A2 (en) * 2003-12-01 2005-06-16 Ipsogen Gene expression profiling of colon cancer by dna microarrays and correlation with survival and histoclinical parameters
JP2007513635A (en) * 2003-12-12 2007-05-31 バイエル・フアーマシユーチカルズ・コーポレーシヨン Gene expression profiles and methods of use
WO2005059109A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
GB0329997D0 (en) * 2003-12-24 2004-01-28 Cancer Rec Tech Ltd Methods for detecting neoplasia and markers thereof
US7264841B2 (en) 2004-01-21 2007-09-04 Linda Kalustian Lester Savory gluten-free foods
WO2005076005A2 (en) * 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
ATE496142T1 (en) 2004-03-23 2011-02-15 Oncotherapy Science Inc METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER
EP1730533A1 (en) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Adam8 as tumor marker and therapeutic target for non-small cell lung cancer
AU2005233564A1 (en) * 2004-04-06 2005-10-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
CA2561947A1 (en) * 2004-04-09 2005-10-20 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
AU2005241093B2 (en) * 2004-05-04 2008-06-05 Institute Of Virology Of Slovak Academy Of Sciences MN/CA IX/ CA9 and renal cancer prognosis
AU2012200098B2 (en) * 2004-05-11 2014-05-08 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumour diagnosis and therapy
AU2013206612B2 (en) * 2004-05-11 2016-04-28 Biontech Ag Identification of surface-associated antigens for tumor diagnosis and therapy
DE102004023187A1 (en) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
EP1774043A4 (en) * 2004-05-28 2009-09-02 Dana Farber Cancer Inst Inc COMPOSITIONS, KITS AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING AND TREATING CANCER
US20120258442A1 (en) 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
KR20070057761A (en) * 2004-06-04 2007-06-07 아비아라디엑스, 인코포레이티드 Confirmation method of tumor
ES2323972T3 (en) * 2004-06-25 2009-07-28 Veridex, Llc METHODS AND REAGENTS FOR THE DETECTION OF MELANOMA.
US20080254031A1 (en) * 2004-09-09 2008-10-16 Exonhit Therapeutics Sa Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
EP1812794A4 (en) * 2004-10-13 2008-09-10 A & G Pharmaceutical Inc AUTOCRINE GROWTH FACTOR RECEPTORS AND METHODS
US7491390B2 (en) 2004-10-15 2009-02-17 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US8337838B2 (en) 2004-10-15 2012-12-25 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
US7641903B2 (en) 2004-10-15 2010-01-05 Seattle Genetics, Inc. Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders
WO2006053442A1 (en) * 2004-11-22 2006-05-26 Diagnocure Inc. Calml3 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
JP2006174731A (en) * 2004-12-21 2006-07-06 Seikagaku Kogyo Co Ltd Translocation agent and method for detecting canceration of tissue
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
KR100689274B1 (en) * 2005-03-30 2007-03-08 김현기 Human primary cancer gene, protein encoded thereby
CN101203241B (en) 2005-04-19 2012-02-22 西雅图基因公司 Humanized anti-CD70 binding agents and uses thereof
EP2177614B1 (en) * 2005-05-02 2014-12-31 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
ES2550652T3 (en) 2005-06-03 2015-11-11 Biotheranostics, Inc. Tumor and tissue identification
US8716021B2 (en) 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
JP2009513125A (en) * 2005-10-28 2009-04-02 ビオメリュー・ソシエテ・アノニム Cancer detection method
GB0526498D0 (en) * 2005-12-28 2006-02-08 Randox Lab Ltd Method
WO2008045133A2 (en) * 2006-03-03 2008-04-17 Veridex, Llc Molecular assay to predict recurrence of dukes' b colon cancer
GB0606954D0 (en) * 2006-04-06 2006-05-17 Randox Lab Ltd Method
AR053600A1 (en) * 2006-04-28 2007-05-09 Fundacion Inst Leloir AN ISOLATED DNA FRAGMENT FROM THE A33 HUMAN PROMOTER AND ITS USE TO DIRECT THE EXPRESSION OF A HETEROLOGICAL GENE IN TUMOR CELLS
EA010571B1 (en) * 2006-08-15 2008-10-30 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Method for diagnosis of non-small cell carcinoma of lung and a kit therefor
JPWO2008029601A1 (en) * 2006-08-16 2010-01-21 株式会社 未来創薬研究所 Cancer therapeutic agent comprising as an active ingredient a ligand for neuromedin U receptor 2 (FM4) molecule
KR20140116546A (en) 2006-10-27 2014-10-02 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
US8822153B2 (en) 2007-06-01 2014-09-02 The University Of North Carolina At Chapel Hill Molecular diagnosis and typing of lung cancer variants
EP2171090B1 (en) * 2007-06-08 2013-04-03 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2009021680A1 (en) * 2007-08-14 2009-02-19 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
CN110079598A (en) * 2007-10-23 2019-08-02 临床基因组学有限公司 Diagnose neoplastic method-II
WO2009101620A1 (en) * 2008-02-11 2009-08-20 Hadasit Medical Research Services & Development Limited Colon cancer associated transcript 1 (ccat1) as a cancer marker
EP2276509B1 (en) 2008-04-11 2016-06-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
US8163551B2 (en) 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010047310A1 (en) 2008-10-20 2010-04-29 大日本住友製薬株式会社 Tumor antigen peptide and use thereof
WO2010062857A1 (en) 2008-11-26 2010-06-03 Allergan, Inc. Klk-13 antibody inhibitor for treating dry eye
WO2011009036A1 (en) * 2009-07-16 2011-01-20 Soymeds, Inc. Soybean derived human thyroglobulin, methods of producing and applications thereof
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP3409287B9 (en) 2010-09-29 2021-07-21 Agensys, Inc. Antibody drug conjugates (adc) that bind to 191p4d12 proteins
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
EP3224377B1 (en) * 2014-11-25 2020-01-01 AIT Austrian Institute of Technology GmbH Diagnosis of lung cancer
JP2016214239A (en) * 2015-05-15 2016-12-22 国立大学法人高知大学 Pancreatic cancer marker
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
MX2021003663A (en) 2018-09-28 2021-05-28 Harvard College CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE THE REGENERATION OF ORGANS AND TISSUES.
IL283522B2 (en) 2018-12-03 2025-03-01 Agensys Inc Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
TWI877278B (en) 2019-12-30 2025-03-21 美商思進公司 Methods of treating cancer with nonfucosylated anti-cd70 antibodies
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5882874A (en) * 1998-02-27 1999-03-16 The Trustees Of Columbia University In The City Of New York Reciprocal subtraction differential display
WO1999050278A1 (en) * 1998-03-31 1999-10-07 Genzyme Corporation Compositions and methods for the identification of lung tumor cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHENG L ET AL: "Characterisations of taxol-induced apoptosis and altered gene expression in human breast cancer cells.", CELLULAR PHARMACOLOGY, vol. 2, no. 6, 1995, pages 249 - 257, XP008013734, ISSN: 1351-3214 *
DATABASE EBI [online] 3 August 1996 (1996-08-03), HILLIER, L. ET AL.: "ze23c03.s1 Soares fetal heart, H. sapiens cDNA clone, mRNA sequence;", XP002230815, retrieved from EMBL Database accession no. AA011199 *
HESS J ET AL: "Application of differential cDNA screening techniques to the identification of unique gene expression in tumours and lymphocytes", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 10, no. 2, April 1998 (1998-04-01), pages 125 - 130, XP004327175, ISSN: 0952-7915 *
KURDISTANI SIAVASH K ET AL: "Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage.", CANCER RESEARCH, vol. 58, no. 19, 1 October 1998 (1998-10-01), pages 4439 - 4444, XP001109678, ISSN: 0008-5472 *
SIAVOSHIAN S ET AL: "Subtractive hybridization and differential screening identified two genes differentially expressed after induction of in vitro (atypical) terminal differentiation in the NSCLC-N6 cell line by a marine substance (bistramide K).", ANTICANCER RESEARCH., vol. 19, no. 6b, November 1999 (1999-11-01), pages 5361 - 5366, XP008013799, ISSN: 0250-7005 *
VIETOR I ET AL: "In search of differentially expressed genes and proteins", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1359, no. 3, 12 December 1997 (1997-12-12), pages 187 - 199, XP004277797, ISSN: 0167-4889 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601826B2 (en) 2002-09-30 2009-10-13 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
US7943730B2 (en) 2002-09-30 2011-05-17 Oncotherapy Science, Inc. Genes and polypeptides relating to human pancreatic cancers
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US12129306B2 (en) 2017-04-03 2024-10-29 Hoffman-La Roche Inc. Antibodies binding to STEAP-1

Also Published As

Publication number Publication date
WO2001094629A8 (en) 2002-05-16
AU2001264559A1 (en) 2001-12-17
EP1358349A2 (en) 2003-11-05
JP2004509612A (en) 2004-04-02
CA2411601A1 (en) 2001-12-13
AU2001264559A8 (en) 2001-12-17
WO2001094629A2 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
WO2001094629A3 (en) Cancer gene determination and therapeutic screening using signature gene sets
MXPA03002862A (en) Cancer diagnostic panel.
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2000028090A3 (en) Diagnostic assay for cancer
WO1998053319A3 (en) Gene expression profiles in normal and cancer cells
WO2002092854A3 (en) Genes expressed in breast cancer as prognostic and therapeutic targets
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO2004031413A3 (en) Method for diagnosing non-small cell lung cancers
WO2002071928A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002059373A3 (en) Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2003068054A3 (en) Identification of ovarian cancer tumor markers and therapeutic targets
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2004018676A3 (en) Rnai probes targeting cancer-related proteins
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2002010436A3 (en) Prognostic classification of breast cancer
WO2001036685A3 (en) Differential gene expression in cancer
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2004005530A3 (en) Compositions and methods for treatment and detection of multiple cancers
WO2004074301A3 (en) Differentially expressed nucleic acids that correlate with ksp expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 50/2001 UNDER "PUBLISHED", DELETE "SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

CFP Corrected version of a pamphlet front page
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001938990

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2411601

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 502169

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2001938990

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001938990

Country of ref document: EP